Treatment with the IL-23 inhibitor significantly improved skin clearance in the pediatric study of children aged 6-17 with ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE: 532523, NSE: ...

Biotechnology firm Biocon on Wednesday said its unit has inked a settlement and license agreement with Amgen Inc., paving the ...

Biocon inks deal with Amgen to market Bosaya & Aukelso biosimilars (Prolia & Xgeva copies) in the US from Oct 2025.

The FDA approved a supplemental new drug application for Tremfya for the treatment of children aged 6 years or older with ...

By ensuring timely wound care, vaccination, immunoglobulin administration, and responsible interaction with animals, rabies ...

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) ...

Bengaluru: Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced ...

Halozyme Therapeutics acquires Elektrofi for $750 million, enhancing drug delivery technology with Hypercon's innovative ...

Biocon Biologics, subsidiary of Biocon, announced a settlement and license agreement with Amgen Inc. that clears the path for the commercialization of Bosaya (denosumab-kyqq) and Aukelso ...

Guselkumab is the first IL-23 inhibitor approved for pediatric plaque psoriasis and active psoriatic arthritis, addressing a significant treatment gap. The PROTOSTAR study showed 56% of children on ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...